Denali Therapeutics Inc.

Contributing Author

Recent Articles by Denali Therapeutics Inc.

Aug-06	Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights DNLI GlobeNewswire
Jul-27	Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026 DNLI GlobeNewswire
Jul-09	Denali Therapeutics to Give Opening Plenary Address at Alzheimer's Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier DNLI DNLI -5.62% GlobeNewswire
Jun-18	Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million DNLI GlobeNewswire
May-21	Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease DNLI GlobeNewswire
May-07	Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights DNLI GlobeNewswire
Apr-03	Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN) DNLI GlobeNewswire
Mar-25	Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II) DNLI +7.15% GlobeNewswire
Feb-26	Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights DNLI GlobeNewswire
Feb-05	Denali Therapeutics Presents Enzyme TransportVehicle Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium DNLI -5.92% DNLI +5.29% GlobeNewswire
Feb-02	Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle Programs at the 2026 WORLDSymposium DNLI GlobeNewswire
Jan-29	Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium DNLI GlobeNewswire
Jan-06	Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome DNLI +7.43% GlobeNewswire
Dec-30	The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics' Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II) DNLI GlobeNewswire
Dec-10	Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants DNLI -10.63% GlobeNewswire
Dec-09	Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants DNLI GlobeNewswire
Dec-04	Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement DNLI +5.84% GlobeNewswire
Nov-06	Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights DNLI GlobeNewswire
Nov-06	Denali Therapeutics Announces Board and Executive Leadership Updates DNLI GlobeNewswire
Oct-13	Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome) DNLI GlobeNewswire
Aug-11	Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights DNLI DNLI -5.03% GlobeNewswire
Jul-07	Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II) DNLI GlobeNewswire
May-06	Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome DNLI -12.63% GlobeNewswire

Denali Therapeutics Inc.

Recent Articles by Denali Therapeutics Inc.

Upgrade your Finviz experience